The seed round, which is one of the largest in Austria to date, was co-led by MMC and MassMutual Ventures.
XUND wants to revolutionize tomorrow’s healthcare by delivering evidence-based solutions to patients and healthcare professionals to help them prevent, manage, and treat diseases. By leveraging AI, XUND can automatically analyse and process millions of medical publications to create the baseline for their solutions.
Proven algorithms that combine symptoms, personal risk factors, and demographic data of the patient identify statistically and medically relevant causes for discomfort. The switch from reactive disease treatment to preventive care and efficient disease management benefits multiple parts of the healthcare ecosystem, including patients, insurers, healthcare providers, and pharma.
Having developed the only API certified as a medical device in their field (approved as class IIa), XUND has gained the trust of several prestigious clients.
XUND will use the new funds to push growth and advance its expansion beyond the DACH region, including new markets across Europe. As a medium-term objective, XUND plans to expand into the US, with entry preparations already underway by a submission to the FDA.
Follow XUND on Linkedin, and read more on the story via Tech.EU.